Kylie D. Mason

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Andrew J. Souers, Erwin R. Boghaert, Scott Ackler et al. · Nature Medicine · 2013 · 2.9K citations

Thrombopoiesis, Thrombosis, Hematological Malignancy +11

The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized

Mark F. van Delft, Andrew H. Wei, Kylie D. Mason et al. · Cancer Cell · 2006 · 1.2K citations · Full text

Apoptosis, Immunology, Cell Death +4

Programmed Anuclear Cell Death Delimits Platelet Life Span

Kylie D. Mason, Marina R. Carpinelli, Jamie I. Fletcher et al. · Cell · 2007 · 1K citations · Full text

Thrombopoiesis, Blood Platelet, Hematology +4

Inhibitor of Apoptosis Proteins Limit RIP3 Kinase-Dependent Interleukin-1 Activation

James E. Vince, W. Wei‐Lynn Wong, Ian E. Gentle et al. · Immunity · 2012 · 484 citations · Full text

Inflammation, Cytokine, Apoptosis +6

Bcl-xL–inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets

Simone M. Schoenwaelder, Kate E. Jarman, Elizabeth E. Gardiner et al. · Blood · 2011 · 338 citations · Full text